Welcome to our dedicated page for Xylem SEC filings (Ticker: XYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xylem Inc. filings document the regulatory disclosures of a public operating company focused on water solutions and resource management. Recent Form 8-K reports furnish quarterly and annual financial results, including press-release exhibits for orders, revenue, earnings measures and guidance-related disclosures.
Other Xylem filings record capital actions such as common-stock repurchase authorization, while definitive proxy materials cover governance, shareholder voting matters and executive compensation disclosures, including equity-award and pay-versus-performance information.
Xylem Inc. executive Stacy Cozad, EVP & Chief Legal Officer, reported equity awards under the company’s incentive plan. She received 5,570 non-qualified stock options at an exercise price of $128.98 per share and 1,563 shares of common stock as a grant.
Both the options and the restricted stock units are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. Following these transactions, she directly holds 5,570 options and 2,303 shares of common stock.
Xylem Inc. executive Michael J. McGann reported a mix of equity grants, vesting, and tax-related share withholdings. He received 5,739 non-qualified stock options at an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
McGann also acquired common stock upon vesting of performance-based stock units granted under the Xylem 2011 Omnibus Incentive Plan, tied to Total Shareholder Return (1,966 shares), Adjusted EBITDA (1,622 shares), Revenue (1,103 shares), and ESG performance (489 shares), plus a 1,610-share restricted stock unit award that vests in thirds on the same 2027–2029 dates. To cover tax liabilities from these vestings, the company withheld 2,073, 213, and 510 shares of common stock at $128.98 per share.
Xylem Inc. EVP & Chief Financial Officer William K. Grogan reported equity compensation grants and associated tax withholdings. On March 2, 2026, he was awarded a non-qualified stock option for 18,228 shares at an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029. He also received 5,116 restricted stock units under the same plan, vesting in one-third increments on those same dates. On March 1, 2026, performance-based stock units granted on March 1, 2023 vested upon achievement of Total Shareholder Return, Adjusted EBITDA and Revenue goals, resulting in acquisitions of 5,551, 4,583 and 3,117 shares of common stock, respectively, including additional shares from dividend reinvestment. To cover tax liabilities from these vestings and a prior restricted stock unit grant, 5,888 and 578 shares of common stock were withheld at $128.98 per share. After these transactions, Grogan directly owned 40,151 shares of Xylem common stock and 18,228 options.
Xylem Inc. executive Rodney Aulick reported equity compensation awards and related tax withholding. On March 2, 2026, he received 5,739 non-qualified stock options with an exercise price of $128.98 and 1,610 restricted stock units under the Xylem 2011 Omnibus Incentive Plan.
The new options and RSUs are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029. The filing also shows a disposition of 238 shares of common stock at $128.98 solely to cover tax liabilities from prior RSU vesting, leaving Aulick with 73,917 common shares held directly.
Xylem Inc. EVP and CPSO Claudia S. Toussaint reported equity compensation grants and related tax withholdings. On March 2, 2026, she received 7,089 non-qualified stock options with an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
She also acquired multiple blocks of common stock upon vesting of performance-based and ESG-related stock units granted in 2021 and 2023 under the Xylem 2011 Omnibus Incentive Plan, and received an additional restricted stock unit award set to vest in three annual tranches beginning March 1, 2027. To cover tax liabilities from these vestings, she disposed of several small blocks of common stock through share withholding at $128.98 per share. Following these transactions, she directly owns 9,342 shares of common stock, and an additional 31,250 shares are held indirectly by the Claudia S. Toussaint Revocable Trust.
Xylem Inc. executive Hayati Yarkadas reported equity awards and related tax withholdings. On March 1 and 2, 2026, he acquired several blocks of Xylem common stock through the vesting of performance-based and other stock units under the Xylem 2011 Omnibus Incentive Plan tied to metrics such as Total Shareholder Return, Adjusted EBITDA, Revenue, and ESG performance.
He also received an award of 8,102 non-qualified stock options at an exercise price of $128.98 per share and an additional award of 2,274 restricted stock units scheduled to vest in three equal installments in 2027, 2028, and 2029. To cover tax liabilities from these vestings, a total of 776 shares of common stock were disposed of through tax-withholding transactions at $128.98 per share. After these transactions, he directly held 33,698 shares of common stock and 8,102 stock options.
Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported several equity compensation transactions. She received a grant of 2,194 non-qualified stock options with a price of $128.98 per share, scheduled to vest in three annual installments beginning March 1, 2027.
On March 1, 2026, she acquired 721, 595, 405 and 489 shares of common stock upon vesting of performance-based and ESG-related stock units granted under the Xylem 2011 Omnibus Incentive Plan, reflecting achievement of performance goals tied to total shareholder return, adjusted EBITDA, revenue and ESG performance. She also received an award of restricted stock units scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.
Related to these vestings, 654, 188 and 150 shares of common stock were withheld at $128.98 per share to cover tax liabilities, reducing her directly held common stock to 4,791 shares after the transactions.
Xylem Inc. reported that its Board of Directors approved a new share repurchase program. The company is authorized to buy back up to $1.5 billion of its common stock. The program has no expiration date, allows open market or other lawful purchases, and may be suspended at the company’s discretion. The authorization does not require Xylem to repurchase any specific amount of shares.
Xylem Inc. is a global water technology company with 2025 revenue of $9.0 billion and about 22,000 employees, designing equipment, digital solutions and services across the water cycle. Operations are organized into four segments: Water Infrastructure, Applied Water, Measurement and Control Solutions, and Water Solutions and Services.
The business is diversified geographically, with $5.2 billion of 2025 revenue from the United States and the rest from Western Europe, emerging markets and other regions. Backlog was $4.615 billion at December 31, 2025, with roughly 60% expected to convert to 2026 revenue.
Xylem emphasizes customer centricity, profitable growth, operational excellence, sustainability leadership and a high‑impact culture. The company has set 2025 and 2030 sustainability goals, updated science‑based emissions targets after the Evoqua acquisition, and is pursuing net zero greenhouse gas emissions across its value chain before 2050.
Xylem Inc. reported strong fourth-quarter and full-year 2025 results, highlighted by record annual revenue of $9.0 billion, up 6% on a reported basis and 5% organically. Full-year earnings per share were $3.92, with adjusted EPS of $5.08, up 19%.
Fourth-quarter revenue was $2.4 billion, up 6% reported and 4% organically, with orders of $2.4 billion, up 9% reported and 7% organically. Adjusted Q4 EPS was $1.42, up 20%, and adjusted EBITDA margin reached 23.2%, driven by productivity savings and pricing.
Net income attributable to Xylem for 2025 was $957 million, or $3.92 per diluted share, and operating income rose to $1.22 billion. Cash and cash equivalents increased to $1.48 billion, while long-term debt decreased to $1.41 billion. The Board declared a quarterly dividend of $0.43 per share, an 8% increase.
For 2026, Xylem forecasts revenue of $9.1–$9.2 billion, 2–4% organic growth, with adjusted EPS of $5.35–$5.60 and an adjusted EBITDA margin of 22.9–23.3%. The company also targets a free cash flow margin of 10.2–11%, reflecting expectations for continued profitable growth.